The impact of statins, ace inhibitors and gastric acid suppressants on pneumonia mortality in a UK general practice population cohorty

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 8, 2009, Pages 697-703

  Myles, Puja R ^a   Hubbard, Richard B ^a   Gibson, Jack E ^a   Pogson, Zara ^a   Smith, Christopher J P ^a   McKeever, Tricia M ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

ACE inhibitors; Epidemiology; Histamine 2 receptor antagonists; Mortality; Pneumonia; Proton pump inhibitors; Statins

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTON PUMP INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG USE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; MORTALITY; PNEUMONIA; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; STOMACH ACID; SURVIVAL RATE; SURVIVAL TIME; UNITED KINGDOM; FEMALE; HEALTH SURVEY; KAPLAN MEIER METHOD; MALE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; STATISTICS; TIME;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; FAMILY PRACTICE; FEMALE; GREAT BRITAIN; HISTAMINE H2 ANTAGONISTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KAPLAN-MEIERS ESTIMATE; MALE; PNEUMONIA; POPULATION SURVEILLANCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTON PUMP INHIBITORS; RISK ASSESSMENT; TIME FACTORS;

EID: 70349766400     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1769     Document Type: Article

References (35)

1. BTS. British Thoracic Society Guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56 (suppl 4): 1-64.
2. Frost FJ, Petersen H, Tollestrup K, Skipper B. Influenza and COPD mortality protection as pleitropic, dose-dependent effects of statins. Chest 2007; 131: 1006-1012. (Pubitemid 46608700)
3. Gryglewski RJ. The Sir Hans Krebs lecture: pharmacology of vascular endothelium. The FEBS Journal 2005; 272: 2956-2967.
4. Wiel E, Pu Q, Leclerc J, et al. Effects of the angiotensin-converting enzyme inhibitor perinopril on endothelial injury and hemostasis in rabbit endotoxic shock. Intensive Care Med 2004; 30: 1652-1659. (Pubitemid 39094969)
5. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The impact of prior outpatient ACE inhibitor use on 30-day mortality for patients hospitalised with community-acquired pneumonia. BMC Pulmonary Medicine 2005; 5(12). doi: 10.1186/1471-2466-5-12 (Pubitemid 41461000)
6. Schleinger RG, Fedson DS, Jick SS, Jick H, Meier C. Statins and the risk of pneumonia: a population-based, nested case-control study. Pharmacotherapy 2007; 27(3): 325-332. (Pubitemid 46327900)
7. Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based perspective. Br Med J 2006; 333(7576): 999.
8. Rafailidis PI, Matthaiou DK, Varbobitis I, Falagas ME. Use of ACE inhibitors and risk of community-acquired pneumonia: a review. Eur J Clin Pharmacol 2008; 64: 565-573.
9. Mortensen EM, Restrepo MI, Anzueto A, Pugh J. The effect of prior statin use on 30-day mortality for patients hospitalised with community-acquired pneumonia. Respir Res 2005; 6(1): 82. (Pubitemid 41410154)
10. Mortensen EM, Pugh MJ, Copeland LA, et al. Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. Eur Respir J 2008; 31: 611-617.
11. Chalmers JD, Singanayagam A, Murray MP, Hill AT. Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 2008; 121: 1002-1007.
12. Thomsen RW, Riis A, Kornum JB, Christensen S, Johnsen SP, Sorensen HT. Preadmission use of statins and outcomes after hospitalization with pneumonia. Arch Intern Med 2008; 168(19): 2081-2087.
13. Laheij R, Van Ijzendoorn M, Janssen M, Jansen J. Gastric acidsuppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther 2003; 18(8): 847-851. (Pubitemid 37323651)
14. Laheij R, Sturkenboom M, Hassings R, Dieleman J, Stricker B, Jansen J. Risk of community-acquired pneumonia and use of gastric acidsuppressive drugs. JAMA 2004; 292(16): 1955-1960. (Pubitemid 39411203)
15. Canani RB, Cirillo P, Roggero P, et al. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006; 117: 817-820. (Pubitemid 46071346)
16. Gulmez SE, Holm A, Frederiksen H, Jensen TG, Pedersen C, Hallas J. Use of proton pump inhibitors and the risk of community-acquired pneumonia. Arch Intern Med 2007; 167: 950-955.
17. Sarkar M, Hennessy S, Yang Y. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med 2008; 149: 391-398.
18. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004; 12: 171-177. (Pubitemid 39534583)
19. Myles PR, McKeever T, Hoare Z, Smith C, Hubbard R. The incidence of pneumonia in the United Kingdom: data from a computerized general practice database. Epidemiol Infect (In press).
20. Myles PR, McKeever T, Hoare Z, Smith C, Hubbard R. The incidence of pneumonia in the United Kingdom: data from a computerized general practice database. Epidemiol Infect 2008; 56(2): 109-114.
21. Mortensen EM, Coley CM, Singer DE, et al. Causes of death for patients with community-acquired pneumonia: Results from the pneumonia outcomes research team cohort study. Arch Intern Med 2002; 162: 1059-1064.
22. Koivula I, Sten M, Makela PH. Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study. Arch Intern Med 1999; 159: 1550-1555. (Pubitemid 29340308)
23. Hedlund JU, Ortquist AB, Kalin ME, Granath F. Factors of importance for the long term prognosis after hospital treated pneumonia. Thorax 1993; 48: 785-789. (Pubitemid 23244338)
24. Mortensen EM, Kapur WN, Chang CH, Fine MJ. Assessment of mortality after long-term follow-up of patients with community-acquired pneumonia. Clin Infect Dis 2003; 37: 1617-1624. (Pubitemid 37549947)
25. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiology 1992; 45(6): 613-619.
26. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Disease 1987; 40(5): 373-383. (Pubitemid 17055592)
27. Adams J, Ryan V, White M. How accurate are Townsend deprivation scores as predictors of self-reported health? A comparison with individual level data. J Public Health 2005; 27(1): 101-106. (Pubitemid 40469267)
28. Morris R, Carstairs V. Which deprivation? A comparison of selected deprivation indexes. J Public Health 1991; 13(4): 318-326.
29. Dupont WD, Plummer WD. PS power and sample size program available for free on the internet. Control Clin Trials 1997; 18: 274.
30. Macfarlane J, Colville A, Guion A, Macfarlane R, Rose D. Prospective study of aetiology and outcome of adult lower-respiratory tract infections in the community. Lancet 1993; 341: 511-514. (Pubitemid 23066084)
31. Woodhead M, Macfarlane J, McCracken J, Rose D, Finch R. Prospective study of the aetiology and outcome of pneumonia in the community. Lancet 1987; 1(8534): 671-674. (Pubitemid 17038913)
32. Macfarlane J, Holmes W, Gard P, Macfarlane R, Rose D. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax 2001; 56(2): 109-114. (Pubitemid 32142674)
33. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol drug saf 2007; 16: 241-249. (Pubitemid 46431687)
34. NICE. Technology appraisal 94: statins for the prevention of cardiovascular events. In, 2006.
35. DH. Coronary heart disease: national service framework for coronary heart disease - modern standards and service models, 2000.